Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 10/20 | 0.38 |
| ▸ | PPARA | Q07869 | 10/20 | 0.38 |
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220200 | 0.94 | FFAR1 (0.42) | FFAR1PPARGPPARAPPARDDRD4 | |
| SCHEMBL5850594 | 0.92 | FFAR1 (0.50) | FFAR1PTGS2PPARGPPARAPPARD | |
| SCHEMBL5217169 | 0.86 | PPARG (0.41) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5218871 | 0.86 | FFAR1 (0.46) | FFAR1PTGS2PPARGPPARAPPARD | |
| SCHEMBL5852086 | 0.85 | PPARG (0.49) | FFAR1PPARGPPARAPPARDFFAR4 | |
| SCHEMBL5850592 | 0.85 | PPARG (0.44) | FFAR1PPARGPPARAPPARDFFAR4 | |
| SCHEMBL5850617 | 0.85 | PPARD (0.46) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5850560 | 0.85 | PPARD (0.46) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5219654 | 0.83 | PPARG (0.39) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5219680 | 0.82 | PPARG (0.53) | FFAR1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153878-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | FFAR1 23/4885PTGS2 885/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.